Hangzhou Bozhirui Biopharmaceuticals

Hangzhou Bozhirui Biopharmaceuticals is a clinical-stage biotechnology company based in China that focuses on the discovery and development of targeted protein degradation (TPD) therapies. Utilizing its proprietary PROTAC and molecular glue technologies, the company develops small molecule drugs designed to degrade disease-causing proteins that are difficult to target with traditional inhibitors. The lead program, BZR-001, is a potent androgen receptor degrader currently in Phase 1 clinical trials for patients with metastatic castration-resistant prostate cancer. The company's platform enables the rapid identification and optimization of degraders with high selectivity and oral bioavailability. Bozhirui is expanding its pipeline to include candidates for other solid tumors and autoimmune disorders. Headquartered in Hangzhou, the firm is backed by prominent venture capital investors specializing in the life sciences sector.